DK2257301T3 - Immunterapi baseret på allogene cancerceller. - Google Patents

Immunterapi baseret på allogene cancerceller.

Info

Publication number
DK2257301T3
DK2257301T3 DK09720311.1T DK09720311T DK2257301T3 DK 2257301 T3 DK2257301 T3 DK 2257301T3 DK 09720311 T DK09720311 T DK 09720311T DK 2257301 T3 DK2257301 T3 DK 2257301T3
Authority
DK
Denmark
Prior art keywords
cancer cells
immunotherapy based
allogeneic cancer
allogeneic
immunotherapy
Prior art date
Application number
DK09720311.1T
Other languages
English (en)
Inventor
Eckhard R Podack
Joseph D Rosenblatt
Koichi Yamazaki
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of DK2257301T3 publication Critical patent/DK2257301T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK09720311.1T 2008-03-03 2009-03-03 Immunterapi baseret på allogene cancerceller. DK2257301T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3342508P 2008-03-03 2008-03-03
PCT/US2009/001330 WO2009114085A2 (en) 2008-03-03 2009-03-03 Allogeneic cancer cell-based immunotherapy

Publications (1)

Publication Number Publication Date
DK2257301T3 true DK2257301T3 (da) 2014-04-28

Family

ID=41065702

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09720311.1T DK2257301T3 (da) 2008-03-03 2009-03-03 Immunterapi baseret på allogene cancerceller.

Country Status (11)

Country Link
US (2) US8475785B2 (da)
EP (2) EP2752193B1 (da)
JP (2) JP2011513399A (da)
KR (1) KR20110009095A (da)
CN (1) CN102014937A (da)
AU (1) AU2009223838B2 (da)
CA (1) CA2717854C (da)
DK (1) DK2257301T3 (da)
ES (1) ES2460899T3 (da)
IL (1) IL207958A (da)
WO (1) WO2009114085A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768122B2 (ja) 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
EP2571522A4 (en) * 2010-05-21 2013-11-20 Univ Miami CANCER TREATMENT
JP6385280B2 (ja) * 2012-01-20 2018-09-05 トーメ クロイツ、フェルナンド 自家癌細胞ワクチン
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JPWO2018199318A1 (ja) * 2017-04-28 2020-03-12 国立大学法人高知大学 抗ｇｐｃ−１抗体
DE102021124078A1 (de) 2021-09-17 2023-03-23 Timm Golüke Kosmetikzusammensetzung zur Anwendung auf der Haut

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5217891A (en) 1987-07-28 1993-06-08 Chiron Corporation DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides
WO1989012455A1 (en) 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0484440A4 (en) 1989-07-28 1993-01-07 Us Health Efficient directional genetic cloning system
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
HUT73383A (en) 1993-03-19 1996-07-29 Boehringer Sohn Ingelheim Process for preparing cancer vaccines
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1995004824A1 (en) 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Generation of dna libraries and retroviral vectors for same
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
DK0769932T3 (da) 1994-07-08 1999-06-23 Baxter Int Implanteret indretning indeholdende tumorceller til behandling af cancer
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997010000A1 (en) 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US6342363B1 (en) 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US20040136951A1 (en) 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
JP4768122B2 (ja) * 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
JP5546084B2 (ja) 1998-05-26 2014-07-09 オプサニテクス エルエルシー 抗原に対する免疫応答を調節する組成物および方法
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6317435B1 (en) 1999-03-08 2001-11-13 Qualcomm Incorporated Method and apparatus for maximizing the use of available capacity in a communication system
CA2375912C (en) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
WO2001078772A1 (en) 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20070292411A1 (en) 2000-11-08 2007-12-20 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20060062786A1 (en) 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214210A1 (en) 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030044386A1 (en) 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1456376A4 (en) 2001-11-16 2006-09-06 Us Gov Health & Human Serv NEW CHIMERAL REV, TAT AND NEF ANTIGENES
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US20050214205A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214208A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214207A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind toTRAIL receptors
US20050214206A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030170756A1 (en) * 2002-02-01 2003-09-11 Thomas Jefferson University Treatment of tumor cells for use in immunotherapy of cancer
CA2477417A1 (en) 2002-02-28 2003-09-04 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003092624A2 (en) 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
EP1534336A4 (en) 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
AU2003265523A1 (en) 2002-08-20 2004-03-11 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
DK1549353T3 (da) 2002-10-09 2010-07-12 Central Iowa Health System Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
US20060148064A1 (en) 2002-10-25 2006-07-06 Srivastava Pramod K Apparatus and method for immunotherapy of a cancer through controlled cell lysis
RU2324493C2 (ru) 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
CA2517274C (en) 2003-02-27 2012-09-18 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
KR100499278B1 (ko) * 2003-07-05 2005-07-01 학교법인 포항공과대학교 로텍산 화합물이 공유결합된 고체 기판 및 이를 이용한바이오칩
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
WO2005030963A1 (en) 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
EP1667701A4 (en) 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
BRPI0508762A (pt) 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
ES2671893T3 (es) 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 y PD-1 en el tratamiento del carcinoma de células renales
WO2006123256A2 (en) 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
WO2007030571A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Identification of targets and development of reagents for testing and molecular imaging of human disease
CN101057975B (zh) 2006-12-13 2012-10-10 中国科学院微生物研究所 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用
EP2109455A2 (en) 2006-12-27 2009-10-21 The Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
IL190438A0 (en) 2008-03-25 2008-12-29 K M B Y Ltd A method of setting a drill for drilling a hole in a bone coaxial to the hole in the nail and aiming device for realizing this method
BRPI0909829B1 (pt) 2008-03-26 2018-11-21 Archroma Ip Gmbh composições aperfeiçoadas de abrilhantamento óptico
WO2009121483A1 (en) 2008-04-02 2009-10-08 Sanofi-Aventis Highly bridged peptides from actinomadura namibiensis
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN102223894A (zh) 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010081738A1 (en) 2009-01-16 2010-07-22 Agirx Limited Vaccine compositions
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
AU2010232490B2 (en) 2009-04-03 2016-08-11 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2571522A4 (en) 2010-05-21 2013-11-20 Univ Miami CANCER TREATMENT
EP2678031A4 (en) 2011-02-23 2015-09-02 Univ Miami COMBINED VACCINATION WITH CELL-BASED GP96-IG-SIV / HIV AND THE RECOMBINANT PROTEIN GP120 FOR PROTECTION AGAINST SIV / HIV
EP2714081A4 (en) 2011-05-27 2015-09-09 Cytocure Llc METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
US20160030659A1 (en) 2013-03-15 2016-02-04 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Also Published As

Publication number Publication date
EP2257301A4 (en) 2013-01-16
EP2752193A1 (en) 2014-07-09
WO2009114085A3 (en) 2009-12-03
CA2717854C (en) 2019-02-19
EP2257301A2 (en) 2010-12-08
IL207958A (en) 2015-09-24
KR20110009095A (ko) 2011-01-27
JP2011513399A (ja) 2011-04-28
JP2014208690A (ja) 2014-11-06
IL207958A0 (en) 2010-12-30
CA2717854A1 (en) 2009-09-17
US20110250229A1 (en) 2011-10-13
WO2009114085A2 (en) 2009-09-17
US20130302376A1 (en) 2013-11-14
US8475785B2 (en) 2013-07-02
AU2009223838A1 (en) 2009-09-17
US9238064B2 (en) 2016-01-19
ES2460899T3 (es) 2014-05-14
CN102014937A (zh) 2011-04-13
AU2009223838B2 (en) 2012-07-26
EP2257301B1 (en) 2014-01-22
EP2752193B1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
DK2257301T3 (da) Immunterapi baseret på allogene cancerceller.
HUE055338T2 (hu) Indolamin-2,3-dioxigenáz-alapú immunterápia
BRPI1009416A2 (pt) célula solar.
BRPI1006897A2 (pt) compostos, composições e métodos de prevenção da metástase de células cancerosas.
NO2021006I1 (no) Quofenix, delafloksacin
BR112012002226A2 (pt) anticorpos muc1.
BRPI1010301A2 (pt) composição.
DK2651436T3 (da) Mycobakterie antigen sammensætning.
DE112009002161A5 (de) Photovoltaikanlage
CL2008000689S1 (es) Protesis mamaria.
BRPI0822950A2 (pt) Estação de carga.
IT1396487B1 (it) Convogliatore.
BRPI0922070A2 (pt) turbina.
BRPI1011794A2 (pt) compartimento.
BR112012002612A2 (pt) calha.
BRPI0815733A2 (pt) Estrutura flutuante.
IT1394801B1 (it) Struttura di lampada.
IT1394641B1 (it) Struttura di rasoio perfezionato.
IT1394901B1 (it) Struttura di lampada.
IT1396642B1 (it) Statore.
FR2943510B1 (fr) Ombrelle.
IT1393750B1 (it) Impianto fotovoltaico
ITME20080002A1 (it) Filcomplex - potabilizzatore di acque.
FR2918073B1 (fr) Cellules fixatrices de cellules tumorales.
FR2945589B1 (fr) Diffuseur.